Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
American Society of Hematology Logo Close
  • ASH Open Menu
    • ASH Home Open External Link
    • ASH Store Open External Link
    • Advocacy Open External Link
    • Education Open External Link
    • Meetings Open External Link
    • Publications Open External Link
    • Research Open External Link
  • ASH Clinical News
  • ASH Image Bank Open External Link
  • ASH News Daily
  • ASH-SAP
  • Blood Journals Open Menu
    • Blood
    • Blood Advances
    • Blood Global Hematology
    • Blood Immunology & Cellular Therapy
    • Blood Neoplasia
    • Blood Red Cells & Iron
    • Blood Vessels, Thrombosis & Hemostasis
  • Hematology
  • The Hematologist
  • International Open Menu
    • Blood Chinese Edition Open External Link
    • Blood Italian Edition Open External Link
    • Blood Latin America Edition Open External Link
    • Blood Spanish Edition Open External Link
Cart
User Tools Dropdown
Cart
Sign In Open Menu
Search Dropdown Menu
header search
    Search
    Blood
    Toggle MenuMenu
    • IssuesOpen Menu
      • Current Issue
      • All Issues
    • First edition
    • AbstractsOpen Menu
      • 2024 Annual Meeting
      • 2024 Late Breaking
      • 2023 Annual Meeting
      • 2023 Late Breaking
      • 2022 Annual Meeting
      • 2022 Late Breaking
      • 2021 Annual Meeting
      • 2020 Annual Meeting
      • 2020 Late Breaking
      • All Meeting Abstracts
    • CollectionsOpen Menu
      • Blood Cover Contest
      • Blood Podcast
      • Collections
      • Special Collections
      • Multimedia
    • Author CenterOpen Menu
      • Alerts
      • Author Guide
      • Style Guide
      • SubmitOpen External Link
      • Why Submit to Blood?
    • AboutOpen Menu
      • About Blood
      • Alerts
      • Blood ClassifiedsOpen External Link
      • Copyright
      • Editorial Board
      • Publications StaffOpen External Link
      • Public Access
      • Subscriptions
    Skip Nav Destination

    Update search

    Querybuilder input 1
    Filter
    • Title
    • Author
    • Full Text
    • Abstract
    • Keyword
    • DOI
    Querybuilder input 2
    Filter
    • Title
    • Author
    • Full Text
    • Abstract
    • Keyword
    • DOI
    Querybuilder input 3
    Filter
    • Title
    • Author
    • Full Text
    • Abstract
    • Keyword
    • DOI
    Querybuilder input 4
    Filter
    • Title
    • Author
    • Full Text
    • Abstract
    • Keyword
    • DOI
    Querybuilder input 5
    Filter
    • Title
    • Author
    • Full Text
    • Abstract
    • Keyword
    • DOI
    Querybuilder input 6
    Filter
    • Title
    • Author
    • Full Text
    • Abstract
    • Keyword
    • DOI

    NARROW

    Publications

    Filter by publications

    Format

    Filter by format

    Article Type

    Filter by article-type

    Topics

    Filter by topics

    Date

    Filter by date
    Apply

    Availability

    Availability
    1-2 of 2
    on Behalf of IRIS Study Group
    Close
    Save search
    Follow your search
    Access your saved searches in your account
    Would you like to receive an alert when new items match your search?
    Close Modal
    Sort by
    Journal Articles

    Declining Rates of Adverse Events (AEs), Rare Occurrence of Serious AEs (SAEs), and No Unexpected Long-Term Side Effects at 5 Years in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Initially Treated with Imatinib (IM) in the International Randomized Study of Interferon vs STI571 (IRIS).

    Free
    Hagop M. Kantarjian, MD, Richard A. Larson, MD, Francois Guilhot, MD, Stephen G. O’Brien, MBChB, PhD, Brian J. Druker, MD, on Behalf of IRIS Study Group
    Journal: Blood
    Blood (2006) 108 (11): 2136.
    https://doi.org/10.1182/blood.V108.11.2136.2136
    Published: 2006
    Journal Articles

    Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

    Free
    Jaspal Kaeda, Andreas Hochhaus, Jerald Radich, Susan Branford, Charlene So, Insa Gathmann, Elisabeth Wehrle, John Goldman, Timothy Hughes, on Behalf of IRIS Study Group
    Journal: Blood
    Blood (2006) 108 (11): 2139.
    https://doi.org/10.1182/blood.V108.11.2139.2139
    Published: 2006

    Advertisement intended for health care professionals

    Email alerts

    First Edition Alert
    Latest Issue Alert
    Close Modal

    Advertisement intended for health care professionals

    Blood
    • About Blood
    • Abstracts
    • Advertising in Blood
    • Alerts
    • All Issues
    • Author Guide
    • Blood Classifieds
    • Collections
    • Contact Us
    • Current Issue
    • First edition
    • Newsroom
    • Permissions
    • Subscriptions
    • Submit to Blood
    • American Society of Hematology
    • 2021 L Street NW, Suite 900
    • Washington, DC 20036
    • TEL +1 202-776-0544
    • FAX +1 202-776-0545
    American Society of Hematology

    ASH Publications

    • Blood
    • Blood Advances
    • Blood Global Hematology
    • Blood Immunology & Cellular Therapy
    • Blood Neoplasia
    • Blood Red Cells & Iron
    • Blood Vessels, Thrombosis & Hemostasis
    • Hematology, ASH Education Program
    • ASH Clinical News
    • ASH-SAP
    • The Hematologist

    American Society of Hematology

    • ASH Home
    • ASH Image Bank
    • ASH Store

    • Advocacy
    • Education
    • Meetings
    • Research
    Copyright 2025 by American Society of Hematology
     
    • Cookie Settings
    • Privacy Policy
    • Cookie Policy
    • Terms of Use
    • Contact Us
    Close Modal
    Close Modal
    This Feature Is Available To Subscribers Only

    Sign In or Create an Account

    Close Modal
    Close Modal

    Advertisement intended for health care professionals